ImageneBio, Inc.
IMA evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $57.7M
What it means
What to watch
Prepared research question
What matters most for IMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMA
ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company developing olevaprubart (IMG-007), a non-depleting anti-OX40 monoclonal antibody for autoimmune and inflammatory diseases, with initial focus on atopic dermatitis and alopecia areata [sec · filed 2026-08-05].
Key risk: Pre-revenue net loss
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$57.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company developing olevaprubart (IMG-007), a non-depleting anti-OX40 monoclonal antibody for autoimmune and inflammatory diseases, with initial focus on atopic dermatitis and alopecia areata [sec · filed 2026-08-05].
- Lead asset olevaprubart (IMG-007) is a non-depleting anti-OX40 monoclonal antibody that blocks OX40-OX40L binding on activated T cells [sec · filed 2026-08-05].
- Initial clinical evaluation targets atopic dermatitis (AD) and alopecia areata (AA), with potential expansion into asthma, rheumatoid arthritis, and hidradenitis suppurativa [sec · filed 2026-08-05].
- Cash & equivalents of $94.7M as of 2026-06-30 [sec]; net income of -$10.2M for the same period [sec].
- Shareholders' equity stood at $142.1M as of 2026-06-30 [sec].
- The company describes olevaprubart as having 'pipeline within a product' potential for multiple immunological indications [sec · filed 2026-08-05].
What works
- Olevaprubart targets the OX40 pathway, which is thought to be important in driving pathogenesis across a spectrum of autoimmune and inflammatory diseases, offering broad therapeutic potential [sec · filed 2026-08-05].
- The company has a cash position of $94.7M as of 2026-06-30, providing a financial runway to support ongoing clinical development [sec].
- ImageneBio is pursuing a 'pipeline within a product' strategy, aiming to address multiple indications (AD, AA, asthma, rheumatoid arthritis, hidradenitis suppurativa) with a single asset [sec · filed 2026-08-05].
What to weigh
- The company reported a net loss of $10.2M for the period ending 2026-06-30, reflecting the pre-revenue stage typical of clinical-stage biopharma [sec].
- Clinical development timelines and outcomes are inherently uncertain; forward-looking statements note risks related to initiating or progressing trials on anticipated timelines [sec · filed 2026-04-13].
- The company faces competition from other anti-OX40 programs and established therapies in autoimmune/inflammatory disease markets [sec · filed 2026-08-05].
- Legal proceedings are ongoing, which could impose financial or operational burdens [sec · filed 2026-08-05].
From the filings
Quoted directly from source documents.
Olevaprubart is a non-depleting anti-OX40 monoclonal antibody.
“non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand”
SEC filings · August 5, 2026
Initial indications are atopic dermatitis and alopecia areata.
“initial evaluation in atopic dermatitis ("AD") and alopecia areata ("AA")”
SEC filings · August 5, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue net loss — Net loss of $10.2M as of 2026-06-30 reflects no product revenue and ongoing R&D spend [sec].
- Clinical trial uncertainty
- Competitive landscape — Competing anti-OX40 programs and established therapies in autoimmune/inflammatory space [sec · filed 2026-08-05].
- Ongoing legal proceedings — Legal proceedings could impose financial or operational burdens [sec · filed 2026-08-05].
What to watch
- Initiation and progress of clinical trials for olevaprubart in atopic dermatitis and alopecia areata [sec · filed 2026-08-05].
- Cash burn rate and any updates to cash runway guidance [sec · filed 2026-08-05].
- Resolution of ongoing legal proceedings and their impact on operations [sec · filed 2026-08-05].
- Any expansion of olevaprubart into additional indications such as asthma or rheumatoid arthritis [sec · filed 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run ImageneBio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ImageneBio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.07
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$26.7M
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 1,110,002 | $5.6M |
| blue owl capital holdings lp | 959,337 | $4.8M |
| cable car capital, lp | 754,749 | $3.8M |
| omega fund management, llc | 455,361 | $2.3M |
| orbimed advisors llc | 378,556 | $1.9M |
| rtw investments, lp | 334,445 | $1.7M |
| vanguard capital management llc | 325,155 | $1.6M |
| bml capital management, llc | 200,730 | $1.0M |
| blackrock, inc. | 129,214 | $646K |
| citadel advisors llc | 124,345 | $622K |
Showing top 10 of 38 institutional holders of ImageneBio, Inc.. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for ImageneBio, Inc.?
ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company developing olevaprubart (IMG-007), a non-depleting anti-OX40 monoclonal antibody for autoimmune and inflammatory diseases, with initial focus on atopic dermatitis and alopecia areata [sec · filed 2026-08-05].
Who is the CEO of ImageneBio, Inc.?
Dr. Kristin Yarema Ph.D. is the chief executive officer of ImageneBio, Inc. (IMA).
Where is ImageneBio, Inc. headquartered?
ImageneBio, Inc. (IMA) is headquartered in San Diego, CA, United States.
What therapeutic areas does ImageneBio, Inc. focus on?
ImageneBio, Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.